Damora Therapeutics (DMRA) Common Equity (2019 - 2026)

Damora Therapeutics (DMRA) has 8 years of Common Equity data on file, last reported at $511.6 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 3631.88% year-over-year to $511.6 million; the trailing twelve-month figure through Mar 2026 stood at $511.6 million (up 3631.88% YoY), and the FY2025 full-year result was $240.4 million, up 1418.41% from the prior year.
• Common Equity for Q1 2026 stood at $511.6 million, up from $240.4 million in the prior quarter.
• Across five years, Common Equity topped out at $511.6 million in Q1 2026 and bottomed at $8.0 million in Q3 2025.
• The 5-year median for Common Equity is $37.4 million (2023), against an average of $79.9 million.
• The widest annual swing landed in 2025, when Common Equity tumbled 61.75%; it then surged 3631.88% in 2026.
• A 5-year view of Common Equity shows it stood at $61.8 million in 2022, then slumped by 47.64% to $32.3 million in 2023, then tumbled by 51.03% to $15.8 million in 2024, then surged by 1418.41% to $240.4 million in 2025, then surged by 112.83% to $511.6 million in 2026.
• The last three Common Equity figures came in at $511.6 million (Q1 2026), $240.4 million (Q4 2025), and $8.0 million (Q3 2025), per Business Quant data.

Peer Comparison